scholarly journals Application of Different Imaging Methods in the Early Diagnosis of Primary Hepatic Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Xin’ai Wu ◽  
Jianbo Li ◽  
Cheng Wang ◽  
Guojian Zhang ◽  
Na Zheng ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Early Stage ◽  
Survival Rates ◽  
Hepatic Carcinoma ◽  
Imaging Methods ◽  
Positron Emission ◽  
Ultrasound Computed Tomography ◽  
Primary Hepatic Carcinoma ◽  
The Common ◽  
The One

Primary hepatic carcinoma (PHC) is the one of the most common tumors and the common cause of cancer death in the world. Detecting PHC in its early stage by imaging methods may greatly increase survival rates of patients. Ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography/computed tomography are common imaging methods in the diagnosis of PHC. In this paper, the application of different imaging methods in diagnosing the primary hepatic carcinoma will be discussed.

scholarly journals Surgical Treatment of Primary Cardiac Paragangliomas: A Single-Center Experience

2021 ◽  
Vol 24 (6) ◽  
pp. E1023-E1026
Author(s):  
Jianjie Zheng ◽  
Jianpeng Li ◽  
Jing Li ◽  
Liang Zhong ◽  
Suochun Xu ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Surgical Treatment ◽  
Surgical Resection ◽  
Immunohistochemical Staining ◽  
Preoperative Imaging ◽  
Single Center ◽  
Positron Emission Tomographic ◽  
Imaging Methods ◽  
Positron Emission

Background: Cardiac paragangliomas are rare neuroendocrine tumors that will cause significant morbidity if left undiagnosed. Because of the paucity of cohort data, their rapid diagnosis and appropriate management still pose unique challenges to cardiac surgeons. We aimed to investigate the clinical features and surgical management of primary cardiac paragangliomas in our single center. Methods: From May 2014 to October 2020, patients diagnosed with primary cardiac paragangliomas retrospectively were reviewed. Demographic data, clinical presentation, preoperative imaging methods, surgical resection, perioperative management, histological analysis, and outcomes were recorded. Postoperative follow up also was reviewed. Results: With multiple imaging methods, including echocardiography, computed tomography, positron-emission tomographic-computed tomography, and biochemical tests, there were five cases of primary cardiac paraganglioma verified by postoperative immunohistochemical staining, two of which were hormonally active. There were no metastatic cardiac paragangliomas, according to positron-emission tomographic-computed tomography, and all patients accepted surgical treatment. Preoperative adrenoceptor blockade was given to hormonally active patients, accordingly. Complete resection of the tumor was accomplished under cardiopulmonary bypass in each case. Tumor distribution included two masses on the roof of the left atrium, two masses in the right atrioventricular groove, and one between the ascending aorta and main pulmonary artery. Immunohistochemical staining for chromogranin, neuron-specific enolase, synaptophysin, and S-100 were positive, which were typical of cardiac paraganglioma. There were no operative deaths. All the patients had an uneventful recovery except one patient who underwent low cardiac output syndrome. During follow up (mean 4.2 years, range 0.6-7.0 years), all patients were well with New York Heart Association class I or II. Only one patient developed thyroid carcinoma three years after surgery but with no paraganglioma recurrence during periodic computed tomography, and this patient recovered well after thyroidectomy. Conclusion: Although cardiac paragangliomas are rare and may present surgical challenges for clinicians, surgical resection remains the choice of treatment with favorable outcomes through a multidisciplinary heart team. Moreover, lifelong surveillance still is recommended to detect possible recurrence or associated nonchromaffin tumors in time.

scholarly journals A Meta-Analysis of Arsenic Trioxide Combined with Transcatheter Arterial Chemoembolization for Treatment of Primary Hepatic Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Ling He ◽  
Qingyun Xu ◽  
Liguo Chen ◽  
Ruixue Chen
Keyword(s):  
Meta Analysis ◽  
Efficacy Rate ◽  
Malignant Tumours ◽  
Hepatic Carcinoma ◽  
Randomized Controlled ◽  
Primary Hepatic Carcinoma ◽  
One Year ◽  
The One ◽  
Arterial Chemoembolization

Primary hepatic carcinoma (PHC) is one of the most common malignant tumours in the world. More and more research has shown that As2O3combined with TACE has a good curative effect in treating PHC. The objectives of this study were to evaluate the therapeutic efficacy and safety of As2O3combined with TACE in treating PHC. The CNKI, VIP, Wanfang, PubMed, and Cochrane databases were searched from their inception until December 2015. Randomized controlled trials (RCTs) comparing As2O3combined with TACE versus TACE alone in treating PHC were identified. Stata SE 12.0 was used for data analysis. 17 RCTs with 1055 patients were included. Meta-analysis showed that, compared with TACE alone, As2O3combined with TACE showed significant effects in improving the clinical efficacy rate (P<0.01), decreasing the value of alpha-fetoprotein (P<0.01), increasing the one-year survival rate (P<0.01), and improving the quality of life of PHC patients (P<0.01). Fifteen studies had mentioned adverse events, but no serious adverse effects were reported in any of the included trials. In conclusion, As2O3combined with TACE therapy appears to be potentially effective in treating PHC and is generally safe. However, further studies with rigorous designs trials and multiregional cooperation trials are needed.

Sign in / Sign up

Export Citation Format

Share Document